The market dynamics for Phenylketonuria (PKU) are witnessing substantial growth driven by increasing neonatal screening programs, growing awareness regarding inherited metabolic disorders, advancements in genetic diagnostics, and the development of novel therapies aimed at improving long-term phenylalanine control. Additionally, the launch of emerging therapies such as Repinatrabit (JNT-517), AG-181, and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Phenylketonuria (PKU) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of PKU, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Key Takeaways from the Phenylketonuria (PKU) Market
-
The market size for PKU in the leading markets is expected to grow significantly by 2036.
-
According to DelveInsight’s analysis, the total market size of PKU in the 7MM was approximately USD 600 million in 2022 and is projected to reach nearly USD 2.1 billion by 2036.
-
The United States accounted for the highest PKU market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.
-
In 2025, the US recorded the highest number of diagnosed prevalent PKU cases among the 7MM, with approximately 18,000 cases. This figure is projected to rise throughout the forecast period from 2026 to 2036.
-
In 2025, the diagnosed prevalent cases of PKU across EU4 and the UK were approximately 32,000, with this number anticipated to grow by 2036.
-
In Japan, the majority of PKU cases in 2025 were reported in the under-14 age group (530 cases), while the fewest cases (40) were observed in individuals aged 45 years and older.
-
In 2025, the majority of severity-specific PKU cases in the US were attributed to classical PKU, accounting for nearly 10,600 reported cases.
-
In 2025, the highest number of mutation-specific PKU cases in Japan were associated with missense mutations (620 cases).
-
Leading PKU companies, such as Otsuka Pharmaceutical, Agios Pharmaceuticals, BioMarin Pharmaceutical, PTC Therapeutics, and others, are actively developing innovative therapies to improve metabolic control and address unmet clinical needs.
-
The promising PKU therapies in development include Repinatrabit (JNT-517), AG-181, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/phenylketonuria-pku-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr
Key Factors Driving the Phenylketonuria (PKU) MarketIncreasing Neonatal Screening and Early Diagnosis
Widespread implementation of newborn screening programs using tandem mass spectrometry has significantly improved early diagnosis and long-term management outcomes for PKU patients.
Growing Demand for Effective Metabolic Control Therapies
Conventional dietary restrictions remain difficult to maintain lifelong. The growing need for therapies capable of sustainably reducing blood phenylalanine levels is driving demand for innovative pharmacological approaches.
Advancements in Gene-Based and Enzyme Replacement Therapies
Emerging therapeutic strategies such as enzyme substitution therapy, transporter inhibition, PAH stabilization, gene therapy, and mRNA-based approaches are expected to transform the PKU treatment landscape.
Rising Awareness Regarding Rare Genetic Disorders
Improved patient advocacy efforts, physician awareness, and rare disease research funding are accelerating diagnosis rates, treatment adoption, and pipeline innovation in PKU.
Phenylketonuria (PKU) Competitive Landscape
-
Several PKU therapies in development include Repinatrabit (JNT-517), AG-181, and others.
-
Repinatrabit (JNT-517), developed by Otsuka Pharmaceutical, is an investigational oral small-molecule therapy designed to selectively inhibit phenylalanine transport, thereby reducing systemic phenylalanine levels and improving metabolic control. The therapy is currently in Phase III development.
-
AG-181, developed by Agios Pharmaceuticals, is an investigational small-molecule PAH stabilizer being evaluated to regulate metabolic pathways involved in phenylalanine metabolism and improve metabolic balance in PKU patients. The therapy is currently in Phase I development.
-
These emerging therapies aim to improve efficacy, metabolic control, patient compliance, and long-term neurological outcomes beyond the limitations of current dietary management strategies.
Discover more about therapies set to grab major Phenylketonuria market share @ Phenylketonuria Treatment Landscape
Recent Developments in the Phenylketonuria (PKU) Market
-
In March 2026, Otsuka Pharmaceutical reported open-label extension data for repinatrabit (JNT-517), showing a 67% mean reduction in blood phenylalanine levels in adolescents with PKU; the data were presented at the ACMG meeting.
-
In February 2026, BioMarin Pharmaceutical reported that the FDA approved a supplemental Biologics License Application (sBLA) for PALYNZIQ (pegvaliase-pqpz), expanding its indication to include pediatric patients aged 12 years and older with PKU.
-
In December 2025, Otsuka Pharmaceutical initiated a global Phase III trial of repinatrabit (JNT-517) for PKU after receiving orphan drug and Rare Pediatric Disease Designation (RPDD) from the FDA.
-
In July 2025, PTC Therapeutics reported FDA approval of SEPHIENCE (sepiapterin) for PKU in patients aged ≥1 month.
-
In January 2026, Agios Pharmaceuticals completed dosing in the Phase I trial of AG-181 and announced plans to initiate Phase Ib studies in PKU patients during 2026.
What is Phenylketonuria (PKU)?
Phenylketonuria (PKU) is a rare inherited metabolic disorder caused by deficiency or dysfunction of the phenylalanine hydroxylase (PAH) enzyme, resulting in the accumulation of phenylalanine in the blood and brain. Elevated phenylalanine levels can lead to severe neurological impairment, intellectual disability, developmental delay, seizures, behavioral disturbances, and psychiatric complications if left untreated.
PKU is typically diagnosed through newborn screening using tandem mass spectrometry, followed by confirmatory plasma phenylalanine testing and molecular analysis of PAH gene mutations. Current treatment focuses on maintaining safe blood phenylalanine levels through lifelong dietary management, specialized medical foods, and pharmacological therapies.
Phenylketonuria (PKU) Epidemiology Segmentation
The PKU epidemiology section provides insights into the historical and current PKU patient pool and forecasted trends for the leading markets. The PKU market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
-
Total Diagnosed Prevalent Cases of PKU
-
Mutation-specific Diagnosed Prevalent Cases of PKU
-
Severity-specific Diagnosed Prevalent Cases of PKU
-
Age-specific Diagnosed Prevalent Cases of PKU
Scope of the Phenylketonuria (PKU) Market Report
-
Therapeutic Assessment: PKU current marketed and emerging therapies
-
Phenylketonuria Market Dynamics: Key Market Forecast Assumptions and Market Outlook
-
Key Companies: Otsuka Pharmaceutical, Agios Pharmaceuticals, BioMarin Pharmaceutical, PTC Therapeutics, and others
-
Key Therapies: PALYNZIQ (pegvaliase-pqpz), SEPHIENCE (sepiapterin), KUVAN (sapropterin dihydrochloride), JAVYGTOR, Repinatrabit (JNT-517), AG-181, and others
-
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
-
Unmet Needs, KOL’s views, Analyst’s views, Phenylketonuria Market Access and Reimbursement
To know more about Phenylketonuria companies working in the treatment market, visit @ Phenylketonuria Clinical Trials and Therapeutic Assessment
Table of Contents
-
Phenylketonuria Market Report Introduction
-
Executive Summary for Phenylketonuria
-
SWOT Analysis of Phenylketonuria
-
Phenylketonuria Patient Share (%) Overview at a Glance
-
Phenylketonuria Market Overview at a Glance
-
Phenylketonuria Background and Overview
-
Phenylketonuria Epidemiology and Patient Population
-
Country-Specific Patient Population of Phenylketonuria
-
Phenylketonuria Current Treatment and Medical Practices
-
Phenylketonuria Unmet Needs
-
Phenylketonuria Emerging Therapies
-
Phenylketonuria Market Outlook
-
Country-Wise Phenylketonuria Market Analysis (2022–2036)
-
Phenylketonuria Market Access and Reimbursement of Therapies
-
Phenylketonuria Market Drivers
-
Phenylketonuria Market Barriers
-
Phenylketonuria Appendix
-
Phenylketonuria Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
-
About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services